Cost-effectiveness of sunitinib in metastatic renal cell carcinoma

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 4, 2011, Pages 383-393

  Purmonen, Timo T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

computer simulation; cost effectiveness; kidney cancer; QALY; RCC; sunitinib

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HUMAN; KIDNEY CARCINOMA; METASTASIS; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PYRROLES; SURVIVAL;

EID: 80051736592     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.33     Document Type: Article

References (55)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 373, 1119-1132 (2009).
2. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34, 193-205 (2008).
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). (Pubitemid 46089672)
5. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006). (Pubitemid 46630489)
6. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006). (Pubitemid 43854967)
7. Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 178, 1883-1887 (2007). (Pubitemid 47538608)
8. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon a in first-line treatment of patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
9. Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 10(3), 305-317 (2010).
10. Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20 (Suppl. 4), iv81-iv82 (2009).
11. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo controlled Phase III trial. Lancet 372, 449-456 (2008).
12. Norum J, Nieder C, Kondo M. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J. Chemother. 22(2), 75-82 (2010).
13. Négrier S, Remák E, Brown Rl, Kim ST, Charbonneau C, Motzer RJ. Economic evaluation of sunitinib vs. interferon-a (IFN-a) in first-line metastatic renal cell carcinoma (mRCC). Eur. J. Cancer 5(Suppl. 4), 303 (2007).
14. Thompson Coon J, Hoyle M, Green C et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol. Assess. 14 (2), 1-184 (2010).
15. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4), 397-409 (1998). (Pubitemid 28140699)
16. Ondrackova B, Demlova R. Sorafenib and sunitinib in metastatic renal cell carcinoma: cost-effectiveness analysis in reimbursement proceedings vs. data from clinical practice. Presented at : ISPOR 13th Annual European Congress. Prague, Czech Republic, 6-9 November 2010.
17. Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J. Clin. Oncol. 26(24), 3995-4000 (2008).
18. Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health 13(6), 837-845 (2010).
19. Benedict A, Figlin RA, Sandström P et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. DOI: 10. 1111/j. 1464-410X. 2010. 09957 (2011) (Epub ahead of print).
20. Remák E, Brown R, Négrier S, Motzer RJ, Kim ST, Charbonneau C. Sunitinib vs. interferon-a (IFN-a) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation. Value Health 10(6), A327-A328 (2007).
21. Remαk E, Mullins CD, Akobundu E, Charbonneau C, Woodruff K. Economic evaluations of sunitinib versus interferon-a (IFN-α) in first-line metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 25(Suppl. 18S) (2007) (Abstract 6607).
22. Topibulpong N, Tanasanvimon S, Parinyanitikul N, Vinayanuwattikun C, Sriuranpong V. economic implications of the first line treatment of advanced renal cell carcinoma in Thailand: a cost-effectiveness analysis. Presentedt at: ISPOR 4th Asia-Pacific Conference. Phuket, Thailand, 5-7 September 2010.
23. Benedict A, Figlin RA, Charbonneau C, Kreif N, Hariharan S, Négrier S. Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States. J. Clin. Oncol. 27 (2009) (Abstract 17556).
24. Remák E, Vioix H, Sandin R, Harmenberg U, Ullen A, Sandstom P. Cost effectiveness analysis of sunitinib, bevacizumab plus interferon-a and temsirolimus as first-line therapy of metastatic renal cell carcinoma in Sweden. Value Health 12(7), A270 (2009).
25. Silverio NM, Yang S, Alemao E. Cost-effectiveness analysis of temsirolimus vs. sunitinib malate in poor prognosis metastatic renal cell carcinoma (mRCC) in Portugal. Value Health 12(7), A271 (2009).
26. Paz-Ares L, del Muro JG, Grande E, Díaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J. Clin. Pharm. Ther. 35(4), 429-438 (2010).
27. Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu- Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin. Ther. 30(2), 382-392 (2008). (Pubitemid 351474383)
28. Garduño-Espinosa J, Contreras- Hernandez I, Mould-Quevedo J, Salinas-Escudero G, Tapia-Valencia J, Davila-Loaiza G. A cost-utility analysis model for the second line treatment of metastatic renal cell carcinoma in Mexico. Value Health 10(3), A132-A133 (2007).
29. Purmonen T, Martikainen JA, Soini EJ, Kataja V, Kellokumpu-Lehtinen PL. Sunitinib malate provides additional survival and value for money as a second line treatment for metastatic renal cell carcinoma (mRCC) - an economic evaluation using Bayesian approach. Value Health 10(6), A337 (2007).
30. van Nooten F, Dewilde S, Van Belle S, Marbaix S. Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium. Value Health 10(6), A329 (2007).
31. Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma: part I - an updated review. Pharmacoeconomics 29(4), 315-329 (2011).
32. Systematic Reviews. CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination. University of York, York, UK (2009).
33. Cochrane Handbook for Systematic Reviews of Interventions. Version 5. 1. 0. Higgins JPT, Green S (Eds). The Cochrane Collaboration (2011).
34. Purmonen T, Nuttunen P, Vuorinen R, Pyrhönen S, Kataja V, Kellokumpu-Lehtinen P. Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta. Oncol. 49(6), 837-843 (2010).
35. Cella D, Michaelson MD, Bushmakin AG et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a Phase III trial: final results and geographical analysis. Br. J. Cancer 102(4), 658-664 (2010).
36. Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-a2a compared with sunitinib. Br. J. Cancer 102(1), 80-86 (2010)
37. Mickisch GH, Schwander B, Escudier B et al. Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon. Outcomes Res. 3, 19-27 (2011).
38. Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 9(34) (2009).
39. Benedict A, Charbonneau C, Hidi J, Kim ST, Négrier S. Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon-a or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): an indirect comparison. J. Clin. Oncol. 26, (2008) (Abstract 5048).
40. Benedict A, Charbonneau C, Kim ST, Négrier S. Cost-effectiveness of sunitinib (SU), sorafenib (SFN), temsirolimus (TMS), and bevacizumab plus interferon-a (BEV/IFN) as 1st-line therapy for metastatic renal cell carcinoma (mRCC) - an indirect comparison. Ann. Oncol. 19(Suppl. 8), 227 (2008).
41. Sandin R, Munir U, Benedict A et al. economic evaluation of sunitinib first-line for metastatic renal cell carcinoma versus sorafenib, temsirolimus and bevacizumab plus interferon-a in the Swedish health service setting. Value Health 11(6), A468 (2008).
42. Munir U, Benedict A, Borgman B et al. Cost-effectiveness of sunitinib (SU) vs sorafenib (SFN), temsirolimus (TMS) and bevacizumab plus interferon-a (BEV/IFN) as first-line therapy for metastatic renal cell carcinoma (mRCC) - adaptation for the Swedish health service. Ann. Oncol. 19(Suppl. 8), 228 (2008).
43. Calvo E, Maroto-Rey P, Gonzalez- Larriba JL et al. Cost-effectiveness (CE) evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Abstract 409. Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010.
44. Diaz S, Calvo E, Maroto P, Puente J, Lopez- Brea M, Castellano D. Cost-effectiveness and cost-utility analysis of sunitinib (SU) vs sorafenib (SFN) and bevacizumab plus interferon-a (BEV/IFN) as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Ann. Oncol. 19(Suppl. 8), 227 (2008).
45. Godoy JI, Cardona AF, Cáceres H et al. Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma in Colombia (ONCOLGroup study). Presented at: ISPOR 2 Latin America Conference, Rio de Janeiro, Brazil, 10-12 September 2009.
46. Godoy JI, Cardona AF, Cáceres H et al. Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study). J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 16150).
47. Cáceres H, Godoy JI, Cardona AF et al. Economic evaluation of sunitinib vs. interferon-a (IFN-a) in first-line treatment of metastatic renal cell carcinoma (mRCC) in Colombia. Value Health 11(3), A100 (2008).
48. Salinas-Escudero G, Contreras- Hernandez I, Mould-Quevedo J. Cost-effectiveness and cost-utility analysis of sunitinib vs sorafenib and bevacizumab plus interferon-a as first-line treatment for metastatic renal cell carcinoma in Mexico. Value Health 12(7), A497 (2009).
49. Mould-Quevedo J, Tenorio C, Vargas J et al. Pharmacoeconomic evaluation of sunitinib malate for first-line treatment of metastatic renal cell carcinoma in Mexico. Presented at: ISPOR 14th Annual International Meeting. Orlando, FL, USA, 18 May 2009.
50. Greenberg D. Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon a and temsirolimus in first line treatment of metastatic renal cell carcinoma in Israel. Value Health 12(3), A42 (2009).
51. Teich V, Hashizume CM, Marinho T, Charbonneau C, Naves A. Economic evaluation of sunitinib vs. interferon-a and bevacizumab plus interferon-a in the treatment of metastatic renal cell carcinoma (ccrm) - Brazilian private health system perspective. Value Health 13(3), A37 (2010).
52. Aiello EC, Muszbek N, Richardet E, Lingua A, Charbonneau C, Remák E. Cost-effectiveness of new targeted therapy sunitinib malate as second line treatment in metastatic renal cell carcinoma in Argentina. Value Health 10(3), A127-A128 (2007
53. Sutent. Summary of product characteristics. European public assessment report www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product- Information/human/000687/ WC500057737.pdf (Accessed 14 February 2011)
54. NICE technology appraisal guidance 169. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma www.nice.org.uk/TA169 (Accessed 2 October 2010)
55. NICE technology appraisal guidance 178. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma www.nice.org.uk/TA178 (Accessed 2 October 2010